Loading clinical trials...
Loading clinical trials...
Heparin-induced thrombocytopenia (HIT) is a pro-thrombotic immunological condition that occurs in some patients exposed to heparin. The incidence of HIT is estimated at 0.1 to 0.3% of patients exposed...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Central Hospital, Nancy, France
NCT00861692 · Heparin-induced Thrombocytopenia Type II
NCT06066762 · Heparin-induced Thrombocytopenia
NCT04842760 · Platelet Disorder, Heparin-induced Thrombocytopenia, and more
NCT03809481 · Heparin-induced Thrombocytopenia
NCT03148912 · Heparin-induced Thrombocytopenia (HIT)
'CHRU Nancy
Vandœuvre-lès-Nancy, Meurthe Et Moselle
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions